Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1621

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Fluticasone Furoate/Vilanterol
DRUG: Vilanterol

Sponsor

GlaxoSmithKline